14160-65-7

Usage

Synthesis Reference(s)

Tetrahedron Letters, 26, p. 451, 1985 DOI: 10.1016/S0040-4039(00)61908-1

Upstream product

• 19719-88-1 ethyl 3-<2-<2-(ethoxycarbonyl)ethyl><1,3>dioxolan-2-yl>propionate 
• 539-47-9 3-(fur-2-yl)crotonic acid 
• 56-23-5 tetrachloromethane 
• 143-19-1 sodium Oleate 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 105-58-8 Diethyl carbonate 
• 623-49-4 ethyl cyanoformate 
• 6317-49-3 4-oxopimelate 
• 107-21-1 ethylene glycol 

Downstream Products

• 63668-52-0 2'-phenyl-1',4',6',7'-tetrahydro-2'H-spiro[[1,3]dioxolane-2,5'-indazol]-3'-one 
• 63668-53-1 2'-(4-nitro-phenyl)-1',4',6',7'-tetrahydro-2'H-spiro[[1,3]dioxolane-2,5'-indazol]-3-one 
• 77793-25-0 C₂₃H₂₇NO₈ 
• 130655-26-4 8-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-1,4-dioxa-spiro[4.5]dec-7-ene-7-carboxylic acid ethyl ester 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 78982-18-0 C₂₃H₂₉NO₈ 
• 813445-18-0 ethyl (R)-8-((1-phenylethyl)amino)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate 
• 1461719-71-0 C₁₉H₂₅NO₄ 

Relevant academic research and scientific papers

GLUCOCORTICOID RECEPTOR MODULATORS

Described herein are glucocorticoid receptor modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.

GLUCOCORTICOID RECEPTOR MODULATORS

Described herein are glucocorticoid receptor modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.

Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2)

We report the synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamides (4) as CCR2 inhibitors for the potential treatment of inflammatory diseases. Several of the compounds display nanomolar binding affinity for CCR2. The in vitro structure-activity

γ-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists

We describe the design, synthesis, and evaluation, of γ-lactams as glycinamide replacements within a series of di- and trisubstituted cyclohexane CCR2 antagonists. The lactam-containing trisubstituted cyclohexanes proved to be more potent than the disubst

Cyclic derivatives as modulators of chemokine receptor activity

The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.

Process of preparing N-ureidoalkyl-piperidines

The present application describes a process of preparing a compound of formula (IV), or salt or stereoisomer thereof: wherein Pg, at each occurrence, is independently selected from an amine protecting group; comprising the steps of reacting a compound of Formula with a reducing agent to give a compound of Formula III: reacting the compound of formula (III) with an amine of formula (IIa) using reductive amination to give the compound of formula (III)

Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity

The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.

N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes modulators of chemokine receptors of formula (I), or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

The present application describes modulators of chemokine receptor activity of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases, as well as autoimmune pathologies such as rheum

Cyclic derivatives as modulators of chemokine receptor activity

The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis, asthma, restinosis, organ transplantation, and